Free Trial
NASDAQ:DOMH

Dominari 8/8/2024 Earnings Report

Dominari logo
$6.49 +0.16 (+2.53%)
As of 09/19/2025 04:00 PM Eastern

Dominari EPS Results

Actual EPS
-$0.51
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Dominari Revenue Results

Actual Revenue
$6.17 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dominari Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Dominari's next earnings date is estimated for Thursday, November 6, 2025, based on past reporting schedules.

Conference Call Resources

Dominari Earnings Headlines

Dominari Holdings Appoints Brian Parsley as Director
What The Silver Boom Could Mean For You…
AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-overlooked metal isn’t just about “green tech” anymore — it’s becoming critical to the AI revolution and modern energy systems. A new report explains why silver may be one of the most undervalued assets in the market today, and how everyday investors can use it to diversify and protect their savings. It also outlines a simple IRS-approved strategy that makes owning silver easier than most people realize.tc pixel
See More Dominari Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dominari? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dominari and other key companies, straight to your email.

About Dominari

Dominari (NASDAQ:DOMH), a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

View Dominari Profile

More Earnings Resources from MarketBeat